Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Shanghai MicroPort MedBot / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (2252 HK)</a> announced flash results for 1H25 where they expect the revenue to rise 70–80% YoY and net loss to narrow down to RMB 125M.</li>
<li>Toumai Laparoscopic Surgical Robot continued to be the main growth driver securing new orders of 18 units and achieving commercial installation of more than 13 units in overseas markets.</li>
<li>MedBot’s recent approvals of Toumai variants, technology advantages, and commercialization strength places it at an inflection point, expected to be back in the black soon.</li>
</ul>



Shanghai MicroPort MedBot Group (2252 HK) announced flash results for 1H25 where they expect the revenue to rise 70–80% YoY and net loss to narrow down to RMB 125M.
Toumai Laparoscopic Surgical Robot continued to be the main growth driver securing new orders of 18 units and achieving commercial installation of more than 13 units in overseas markets.
MedBot’s recent approvals of Toumai variants, technology advantages, and commercialization strength places it at an inflection point, expected to be back in the black soon.


MicroPort MedBot (2252 HK): Growth Flash Amid Favorable Momentum with Approvals and Overseas Sales

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> has submitted the Hugo robotic-assisted surgery system to the FDA for a urologic indication in 1Q25. In clinical trial, Hugo met the safety and effectiveness endpoints.</li>
<li>Approval is expected in 2H25. Medtronic expects Hugo would contribute to the company’s surgical business in FY26 and will be ‘a meaningful growth driver’ for the company in the medium-term.</li>
<li>Medtronic is well-positioned for accelerated growth, driven by momentum in some of the most attractive growth markets in MedTech. The U.S. approval of Hugo is an icing on the cake.</li>
</ul>



Medtronic Plc (MDT US) has submitted the Hugo robotic-assisted surgery system to the FDA for a urologic indication in 1Q25. In clinical trial, Hugo met the safety and effectiveness endpoints.
Approval is expected in 2H25. Medtronic expects Hugo would contribute to the company’s surgical business in FY26 and will be ‘a meaningful growth driver’ for the company in the medium-term.
Medtronic is well-positioned for accelerated growth, driven by momentum in some of the most attractive growth markets in MedTech. The U.S. approval of Hugo is an icing on the cake.


Medtronic Plc (MDT US): New Approvals to Accelerate Growth Ahead; A Good Time to Buy

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Intuitive Surgical Inc.'s recent earnings reveal a mixed performance with both strengths and challenges.</li><li>Positively, the company reported strong operational outcomes in the first quarter of 2025.</li><li>Da Vinci procedures saw a substantial 17% growth, driven predominantly by robust performances in general surgery across the US and certain international markets, such as India and Korea.</li></ul>

Intuitive Surgical Inc.'s recent earnings reveal a mixed performance with both strengths and challenges.Positively, the company reported strong operational outcomes in the first quarter of 2025.Da Vinci procedures saw a substantial 17% growth, driven predominantly by robust performances in general surgery across the US and certain international markets, such as India and Korea.

Intuitive Surgical: Procedure Growth & Market Expansion to Strengthen Its Market Position!

<ul>
<li>
<a href="https://www.smartkarma.com/entities/intuitive-surgical-inc" target="_blank" data-smartkarma-citation="entities:15853:1" rel="noopener">Intuitive Surgical (ISRG US)</a> revenue grew 19% YoY to $2.3B in 1Q25.  Procedures volume grew ~17% YoY, which boosted instruments and accessories revenue.</li>
<li>The company placed 367 da Vinci surgical systems, compared with 313 in 1Q24. It included 147 da Vinci 5 systems, compared with 8 in the same period last year.</li>
<li>Intuitive has raised the procedure growth guidance range from 13–15% to 15–17%, while trimming down gross margin to the range 65–66.5% from 67–68%, due to tariffs.</li>
</ul>



Intuitive Surgical (ISRG US) revenue grew 19% YoY to $2.3B in 1Q25.  Procedures volume grew ~17% YoY, which boosted instruments and accessories revenue.
The company placed 367 da Vinci surgical systems, compared with 313 in 1Q24. It included 147 da Vinci 5 systems, compared with 8 in the same period last year.
Intuitive has raised the procedure growth guidance range from 13–15% to 15–17%, while trimming down gross margin to the range 65–66.5% from 67–68%, due to tariffs.


Intuitive Surgical (ISRG US): Strong 1Q Result; Tariffs to Impact Margin

<ul><li>Intuitive Surgical Inc. delivered strong financial and operational performance in 2024, signaling significant advancements in their robotic-assisted surgery systems.</li><li>During the fourth quarter earnings discussion, leadership outlined the various factors contributing to the strong annual growth, as well as some of the strategic goals they aim to achieve in 2025.</li><li>One major positive highlighted was the successful early adoption of the fifth-generation da Vinci platform, alongside continued utilization of the Ion and da Vinci SP systems.</li></ul>

Intuitive Surgical Inc. delivered strong financial and operational performance in 2024, signaling significant advancements in their robotic-assisted surgery systems.During the fourth quarter earnings discussion, leadership outlined the various factors contributing to the strong annual growth, as well as some of the strategic goals they aim to achieve in 2025.One major positive highlighted was the successful early adoption of the fifth-generation da Vinci platform, alongside continued utilization of the Ion and da Vinci SP systems.

Intuitive Surgical’s Biggest Moat Is NOT What You Think – Here’s Why It’s a Game-Changer!

United States

Intuitive Surgical, Inc. design, manufactures, and markets surgical systems. The Company offers endoscopes, endoscopic retractors and disectors, scissors, scalpels, forceps, needle holders, electrocautery, ultrasonic cutters, and accessories during surgical procedures. Intuitive Surgical operates worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Intuitive Surgical (ISRG US)

MicroPort MedBot (2252 HK): Growth Flash Amid Favorable Momentum with Approvals and Overseas Sales

Shanghai MicroPort MedBot expects 70–80% revenue growth in 1H25, with net loss narrowing to RMB 125M. Toumai Laparoscopic Surgical Robot is...

Tina Banerjee

Medtronic Plc (MDT US): New Approvals to Accelerate Growth Ahead; A Good Time to Buy

Medtronic submits Hugo robotic-assisted surgery system to FDA for urologic indication, with expected approval in 2H25. Hugo is poised to be a...

Tina Banerjee

Intuitive Surgical: Procedure Growth & Market Expansion to Strengthen Its Market Position!

Intuitive Surgical Inc.'s recent earnings reveal a mixed performance with both strengths and challenges. Positively, the company reported strong...

Baptista Research